Advanced Parkinson's disease causes further deterioration in the physical and cognitive functions of patients with existing Parkinson's disease. This commentary critically assesses an economic evaluation which compared the cost-effectiveness of levodopa/carbidopa intestinal gel against standard of care in treating patients with advanced Parkinson's disease. While the economic evaluation indicated that levodopa/carbidopa intestinal gel could be cost-effective within the UK parameters, the authors of this commentary highlight important limitations related to its design, modelling and analysis. Future research should consider the incorporation of a separate arm dedicated to the re-infusion of apomorphine in eligible patients with advanced Parkinson's disease, a wider set of levodopa/carbidopa intestinal gel adverse events and related costs, and a sub-group analysis on different socioeconomic strata.